Phase 3 Deucrictibant HAE Prophylaxis Trial Marked Completed

A clinical trial update dated November 6, 2026 reports that a Phase 3 study of oral deucrictibant extended-release tablets has reached completed status. The trial, registered as NCT06669754, examined deucrictibant as prophylaxis against angioedema attacks in adolescents and adults with hereditary angioedema (HAE). The study title specifies its focus on prevention of attacks rather than acute treatment. No results, efficacy data, or safety findings were included in this update. The listing confirms only the trial phase, its completed status, and the associated date. Bradykinin signaling is relevant to hereditary angioedema research, and deucrictibant is studied in this therapeutic context, though this update does not report any outcome data tied to bradykinin pathways specifically. Readers should note that completion of a trial refers to the study reaching its defined endpoint timeline or conclusion as recorded on ClinicalTrials.gov, not a determination of safety or benefit. Further details, including any results, would be expected in subsequent postings to the same registry entry. This compound remains classified under unapproved research status. For background on bradykinin and its role in related research areas, readers can consult the compound overview.